Digital Health Investment Insights

HealthTech AI is no longer exciting. It’s expensive. And the market has re-priced itself for performance. The first half of 2025 solidified a new reality in digital health. US-based digital health startups secured $6.4 billion across 245 deals (Rock Health). While total funding is up from H1 2024, the trend of fewer, larger checks persists. Rock Health pegs the average deal size at a robust $26.1 million, a significant increase from $20.4 million in 2024, signaling a concentrated investment in more mature, impactful companies. Investors are no longer buying potential. They're buying precision and demonstrable value. They care if your AI: Saves hours, not just clicks: The focus is on quantifiable time savings for clinicians and administrative staff, directly addressing burnout and efficiency gaps. Cuts costs, not just code: Real-world cost reduction is paramount, whether through optimized operations, reduced errors, or improved resource allocation. Embeds in real workflows, not pitch decks: Solutions need to be seamlessly integrated into existing healthcare systems, proving their utility in daily practice. McKinsey calls this the "productivity premium," and it has become the new funding filter. A significant portion of VC dollars continues to flow into AI-enabled startups, not because they're novel, but because they perform and deliver tangible returns. Abridge: This AI note-taking startup for doctors raised a staggering $316 million in June 2025 (Series E), bringing its total funding to over $770 million. Its value proposition is clear: giving clinicians hours back by automating documentation. Innovaccer: Secured $275 million in Series F funding in January 2025 to expand its AI and cloud capabilities, aiming to be a "one-stop shop" for healthcare AI solutions. They focus on data aggregation and intelligence to optimize value-based care programs and reduce administrative burden. Truveta: Raised $320 million in Series C funding in January 2025, solidifying its position in health data and analytics. Their mission revolves around leveraging data to drive insights and improve care. Hippocratic AI: Completed a $141 million Series B financing round in February 2025, valuing the company at $1.64 billion. Their focus is on developing safe, patient-facing AI for non-diagnostic tasks, addressing healthcare staffing shortages. These companies optimize operations, not optics. The delta? Execution. This is not a hype cycle. It’s a competency correction. The end of vision-only founders. The rise of operator-founders who understand: Unit economics: The true cost and value generated by each patient interaction or service delivered. Integration latency: The speed and ease with which new technologies can be embedded into complex, often legacy, healthcare IT infrastructure. Reimbursement drag: Navigating the intricate and often slow process of getting innovative solutions covered by payers. What part of this feels uncomfortably true?

Q1 2025 Digital Health Funding Hits $3B as Partnering and Channel Strategies Drive Bold Moves: 🔘U.S. digital health funding hit $3B in Q1 2025 across 122 deals, with average deal size jumping to $24.4M from $15.5M in Q4 2024 🔘Early-stage rounds (Seed, Series A/B) made up 83% of deals, including large raises like Hippocratic AI $141M Series B and OpenEvidence $75M Series A 🔘Late-stage megadeals returned, with Innovaccer ($275M), Abridge ($250M), and Qventus, Inc ($105M) driving the Series D+ median to $105M—the highest since 2021 🔘“Tapestry weaving” (strategic M&A to stitch new capabilities into existing offerings) grew, e.g. H1 acquiring Ribbon Health to expand into payer/provider products, hims & hers acquiring Trybe Labs to add at-home testing 🔘Modular tech stacks (flexible, swappable tech infrastructure) gained traction, e.g. Ping An Health integrating DeepSeek AI within a month; Lumeris using 60+ interchangeable LLMs in its agentic AI platform ‘Tom’ 🔘Channel partnerships (multi-partner networks for distribution) expanded, e.g., Eli Lilly and Company grew its LillyDirect platform (I have been calling this out for a while!) Wheel and Huma launched a D2C access joint venture. 🔘Incumbents engaged disruptors to stay ahead, e.g., Lilly partnered with Ro for lower-cost GLP-1 access, Labcorp invested in Teal Health at-home cervical cancer screening 💬 This mirrors a lot of my reporting, a focus on partnerships to expand capabilities and reach and deeper integration. Expect more of this in the next quarters! 👇Link to Rock Health Report and article below #DigitalHealth #Pharma #Funding

The global HealthTech funding map may just be rebalacing. Here's where capital is flowing in 2026. 🇬🇧 𝗨𝗞: £𝟯𝟬𝗠 𝗛𝗲𝗮𝗹𝘁𝗵𝗧𝗲𝗰𝗵 𝗔𝗱𝗼𝗽𝘁𝗶𝗼𝗻 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗙𝘂𝗻𝗱 The NHS didn't release £30M for more pilots. They released it for adoption infrastructure. The difference matters. The UK has innovation fatigue. What NHS needs now is implementation confidence. The companies winning this capital understand that "innovative technology" doesn't unlock procurement anymore. Demonstrable adoption pathways do. If your pitch deck still leads with features, you're solving 2023's problem. 🇪🇺 𝗘𝘂𝗿𝗼𝗽𝗲: €𝟭𝟰𝗕 𝗛𝗼𝗿𝗶𝘇𝗼𝗻 𝗘𝘂𝗿𝗼𝗽𝗲 𝟮𝟬𝟮𝟲-𝟮𝟬𝟮𝟳 Europe just approved €14 billion for Horizon Europe's 2026-2027 work programme. Health, digital, and AI infrastructure are prioritised. Calls opening throughout Q1. This isn't academic R&D. This is infrastructure capital for companies building cross-border data systems, AI diagnostics, and interoperable health platforms. Europe is betting on systems, not apps. Single-market solutions won't capture this. Multi-country architecture will. 🌍 𝗔𝗳𝗿𝗶𝗰𝗮: $𝟰.𝟭𝗕 𝗧𝗼𝘁𝗮𝗹 𝗙𝘂𝗻𝗱𝗶𝗻𝗴 (+𝟮𝟱% 𝗬𝗼𝗬), 𝗛𝗲𝗮𝗹𝘁𝗵𝗧𝗲𝗰𝗵 +𝟮𝟯𝟮% African tech funding hit $4.1 billion in 2025, up 25% year-over-year. HealthTech specifically? $215M. Up 232%. This marks the first time since 2021-2022 that non-fintech sectors exceeded $200M in annual equity funding. The ecosystem isn't emerging anymore. It's executing. Where it's concentrating: → Kenya: $1.04B raised (+72% YoY) → Kenya, South Africa, Egypt, Nigeria: 72% of total capital The 'Africa is too early for HealthTech' narrative just died. Thank you to Rowena Luk from Africa Health Ventures for the data. What the three signals tell us: • UK is funding adoption infrastructure. • Europe is funding cross-border systems. • Africa is funding B2B backbone. • The global theme? Capital is flowing to implementation, not innovation theater. If you're post-Series A and your funding strategy still assumes investors reward potential over proof, you're pricing for the wrong market cycle. ----- ⭐I’m Sara - a HealthTech strategic advisor, fractional operator, and 4x founder who’s scaled ventures to £10M+ ARR across the UK, Europe and Africa. I help founders navigate complexity, rebuild strategic clarity, and scale sustainably. Founder of Well Purposed.

Cardiovascular disease is the largest category in healthcare, and arguably one of the most broken.... It’s the #1 cause of death in the U.S., impacting ~131M adults and driving ~$627 BILLION in annual cost. And yet, despite decades of clinical innovation, the system is still largely reactive, fragmented, and episodic. The science isn't the problem. The delivery model is. At 7wire Ventures, we’ve been spending time digging into this space and published our latest market map + perspective on where things are headed. A few things we’re seeing: 💠 The problem isn’t a lack of innovation, it’s a lack of longitudinal ownership. Care today is triggered by acute events, not continuous management, which is why small gaps in care compound into catastrophic outcomes 💠 The real constraint isn’t data, it’s action. We’re generating more signals than ever, but without triage, prioritization, and workflow integration, it doesn’t translate into better care 💠 The category is shifting from episodic cardiology to chronic, cardiometabolic care. CVD rarely exists in isolation, it’s deeply intertwined with diabetes, obesity, and kidney disease, demanding integrated models 💠 The biggest opportunity is in platforms that own the patient relationship over time, combining monitoring, medication optimization, and care coordination to actually change outcomes 💠 Investors are starting to lean in. CVD digital health funding reached $3.6B in 2025, with deal volume at a 6-year high, particularly concentrated in monitoring and medication optimization If the last decade of digital health was about access and point solutions, the next will be about accountability and longitudinal care. Incumbents like Rush University Medical Center, Astellas Pharma, American Heart Association, and more leading the way partnering with some of the best digital health companies like Heartbeat Health, Karoo Health, Chamber, 9amHealth, Hello Heart, and so many others. 🫀 Cardiovascular disease is where that shift becomes unavoidable. Full market map + our perspective 👇

Capital is still moving in digital health — but it’s doing so with far more intent. 2025 didn’t mark a retreat in global venture funding. It marked a reallocation. Money flowed toward therapeutic areas and clusters that solve immediate, measurable healthcare problems — and away from those still searching for proof of impact. Oncology remained the most funded therapeutic area at $3.6B. But the headline number hides a harder truth: funding declined 12% year over year. That’s not a loss of belief in oncology. It’s investor discipline catching up to complexity, timelines, and capital intensity. Oncology is still essential — but fewer bets are being placed, and only on platforms with clear differentiation. The more interesting signal sits elsewhere. Preventive Health surged 104% in 2025. That’s not a rounding error. That’s conviction. Companies like Neko Health and ŌURA didn’t just raise capital — they validated a thesis: prevention is no longer a wellness side quest. It’s becoming core healthcare infrastructure. Continuous monitoring, risk detection, and proactive intervention now look investable at scale. The same story is playing out across digital health clusters. Health Management Solutions grew 50% year over year, overtaking Research Solutions to become the top-funded cluster. Meanwhile, Research Solutions aka TechBio fell 19%, and Medical Diagnostics dropped 33%. This isn’t anti-science. It’s pro-execution. Investors are prioritising platforms that help systems run better today — care coordination, chronic disease management, workflow optimisation — over tools that promise future insight but lack near-term revenue gravity. Telemedicine (+55%) and Wellness (+74%) reinforce the pattern: adoption, not novelty, is driving checks. My takeaway: 2025 funding data isn’t about optimism or pessimism. It’s about selectivity. Capital is flowing to business models that shorten feedback loops, prove outcomes, and integrate into real healthcare workflows — not just impressive decks. If you’re building in digital health, the bar is clear: Show where you sit in the care journey. Show who pays. Show why now. If you’re navigating this shift, I’m happy to compare notes. Further Reading Report: https://lnkd.in/efRBp676 Op-ed: https://lnkd.in/eBzrUbDY Research: https://lnkd.in/efqcmmzH #DigitalHealth #HealthTech #VentureCapital #techbio #prevention #2025

Digital health funding is up in H1 2026. But that's not the interesting part. The interesting part: investors have stopped asking "who has #AI." Everyone has it now. The real question is "who has something AI alone can't provide." That shift shows up in the data. Mega deals ($100M+) now make up 45% of all capital, up from 22% in 2024. Capital is concentrating around fewer, more defensible bets. I've seen this play out in wearables and connected care. The tech was rarely the differentiator. It was workflow fit, clinical trust, and execution. ŌURA filed its S-1 this year at an $11B valuation. WHOOP raised $575M at $10.1B. Proof that data moats, not device specs, are what scale into real businesses. If AI commoditizes the baseline, judgment and execution become the moat. Is AI raising or lowering the bar for differentiation in health tech right now? #DigitalHealth #HealthTech #Wearables #HealthcareInnovation #HealthcareAI

#DigitalHealth startups raised $7.4B across 244 deals in the first half of 2026, according to Rock Health's latest market report. More importantly, the report highlights a shift that many healthcare founders are already feeling in the market: 💡 AI alone is no longer enough. A few key points from Becker's Healthcare summary: ✅ Capital is flowing, but it's concentrating around fewer, larger winners. Mega rounds accounted for 45% of invested capital despite representing only a small percentage of deals. ✅ Healthcare domain expertise matters. Investors are increasingly looking for founders who deeply understand the clinical, operational, and administrative challenges they are solving. ✅ The question is no longer "Do you have AI?" It's "What can you deliver that AI alone cannot replicate?" As foundation models become more accessible, durable differentiation comes from workflow integration, trust, data, customer relationships, and measurable outcomes. ✅ Health systems want partners, not just products. The report notes growing demand for vendors who can embed with customers and adapt solutions to real world workflows. Implementation and adoption may become just as important as innovation itself. ✅ Several of the strongest companies are expanding beyond point solutions and moving toward owning larger portions of the healthcare operating layer. 🚀 For HLS startups: the winners will combine domain expertise, workflow transformation, customer intimacy, and measurable ROI. 🤔 Which of these trends resonate with you? 👉 Full report here: https://lnkd.in/ek7j_H7V https://lnkd.in/eWh6iYWW Microsoft for Startups Microsoft for Healthcare #StartupSuccess #AIinHealthcare #HealthcareOnLinkedIn

Rock Health’s H1 2025 overview shows AI-enabled startups captured 62% of digital health venture funding.   That doesn’t mean “AI feature” wins. It means capital is chasing proof.   But the more important signal is where the money is concentrated. 👉 Rock Health’s top three funded value props in H1 2025 were: - non-clinical workflow ($1.9B) - clinical workflow ($1.9B) - data infrastructure ($893M)   That’s a bet on workflow ownership and infrastructure that buyers and investors can underwrite in a noisy market: 𝘮𝘦𝘢𝘴𝘶𝘳𝘢𝘣𝘭𝘦 𝘵𝘩𝘳𝘰𝘶𝘨𝘩𝘱𝘶𝘵, 𝘧𝘦𝘸𝘦𝘳 𝘦𝘹𝘤𝘦𝘱𝘵𝘪𝘰𝘯𝘴, 𝘢𝘯𝘥 𝘧𝘢𝘴𝘵𝘦𝘳 𝘤𝘺𝘤𝘭𝘦 𝘵𝘪𝘮𝘦𝘴.   If your AI sits next to the workflow, it will always be a feature. If it owns the workflow end-to-end, it becomes operating leverage.   💡 Where do you think workflow ownership matters most right now: patient access, RCM, or clinical documentation?   #HealthcareAI #DigitalHealth #HealthTech #HealthcareOperations   If you want more posts like this, follow me. I share what I’m seeing at the intersection of AI, operations, and healthcare economics weekly.